Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Operating Activities
Net loss	$ (10,500)	$ (59,411)
Adjustments to reconcile net loss to cash (used in) provided by operating activities:
Depreciation and amortization	12,986	15,252
Credit loss expense	305	10,217
Write-downs	213	4,403
Deferred income tax expense	158	5,627
Share-based and other non-cash compensation	5,421	4,309
Unrealized foreign currency exchange loss	(113)	(223)
Realized and unrealized investment gains (losses)	5,248	(4,539)
Equity in losses of investees	0	529
Changes in assets and liabilities:
Accounts receivable	(13,744)	28,191
Inventories	437	(18,344)
Film assets	(2,213)	(3,064)
Deferred revenue	5,276	8,807
Changes in other operating assets and liabilities	(4,155)	4,688
Net cash (used in) provided by operating activities	(10,951)	5,966
Investing Activities
Purchase of property, plant and equipment	(466)	(271)
Investment in equipment for joint revenue sharing arrangements	(1,540)	(1,580)
Acquisition of other intangible assets	(1,507)	(862)
Proceeds from sale of equity securities	17,769
Net cash provided by (used in) investing activities	14,256	(2,713)
Financing Activities
Proceeds from issuance of convertible notes, net	223,675
Purchase of capped calls related to convertible notes	(19,067)
Revolving credit facility borrowings		280,000
Repayments of revolving credit facility borrowings	(255,000)
Credit facility amendment fees paid	(32)
Settlement of restricted share units and options		(1,667)
Treasury stock repurchased for future settlement of restricted share units		(1,419)
Repurchase of common shares, IMAX China		(36,624)
Taxes withheld and paid on employee stock awards vested	(3,045)	(236)
Common shares issued - stock options exercised	824
Net cash (used in) provided by financing activities	(52,645)	239,163
Effects of exchange rate changes on cash	(245)	377
(Decrease) increase in cash and cash equivalents during period	(49,585)	242,793
Cash and cash equivalents, beginning of period	317,379	109,484
Cash and cash equivalents, end of period	$ 267,794	352,277
IMAX China
Financing Activities
Repurchase of common shares, IMAX China		$ (891)